NASDAQ · Financial Statements

Compass Therapeutics, Inc. (CMPX) Financial Statements

$0.76 NASDAQ: CMPX Market Cap $137.05M

Compass Therapeutics, Inc. most recently reported annual revenue of $0, a net loss of $66.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

Compass Therapeutics, Inc.: net profit was positive in 0 of 8 reported years; the most recent year shows a net loss of $66.0M.

Income Statement — 8 Years (USD millions)

Metric	2018	2019	2020	2021	2022	2023	2024	2025
Revenue	$0	$0	$0	$0	$0	$0	$1.0M	$0
Operating Expenses	$38.0M	$34.0M	$28.0M	$82.0M	$42.0M	$50.0M	$57.0M	$73.0M
Operating Profit	$-38.0M	$-34.0M	$-28.0M	$-82.0M	$-42.0M	$-50.0M	$-57.0M	$-73.0M
Operating Margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	-6661.8%	0.0%
Other Income	$0	$-1.0M	$-2.0M	$0	$2.0M	$8.0M	$7.0M	$6.0M
Interest	$1.0M	$1.0M	$1.0M	$0	$2.0M	$0	$0	$0
Depreciation	$2.0M	$2.0M	$2.0M	$2.0M	$2.0M	$2.0M	$2.0M	$1.0M
Profit Before Tax	$-38.0M	$-35.0M	$-29.0M	$-82.0M	$-39.0M	$-42.0M	$-49.0M	$-66.0M
Tax	$-270,000	$-260,000	$-110,000	$0	$0	$0	$0	$0
Net Profit	$-38.0M	$-35.0M	$-29.0M	$-82.0M	$-39.0M	$-42.0M	$-49.0M	$-66.0M
EPS	$-7.66	$-0.67	$-0.52	$-1.31	$-0.35	$-0.33	$-0.36	$-0.42
Dividend Payout	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Quarterly Results — Last 12 Quarters (USD millions)

8 duplicate period labels in the source data were collapsed.

Metric	Sep '23	Dec '23	Mar '24	Jun '24	Sep '24	Dec '24	Mar '25	Jun '25	Sep '25	Dec '25	Mar '26	Jun '26
Revenue	$0	$0	$0	$1.0M	$0	$0	$0	$0	$0	$0	$0	$0
Operating Expenses	$12.0M	$15.0M	$13.0M	$16.0M	$12.0M	$17.0M	$18.0M	$21.0M	$16.0M	$18.0M	$20.0M	$27.0M
Operating Profit	$-12.0M	$-15.0M	$-13.0M	$-15.0M	$-12.0M	$-17.0M	$-18.0M	$-21.0M	$-16.0M	$-18.0M	$-20.0M	$-27.0M
Operating Margin	0.0%	0.0%	0.0%	-1770.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Interest	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Profit Before Tax	$-10.0M	$-13.0M	$-11.0M	$-13.0M	$-10.0M	$-15.0M	$-17.0M	$-20.0M	$-14.0M	$-16.0M	$-18.0M	$-25.0M
Tax	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Net Profit	$-10.0M	$-13.0M	$-11.0M	$-13.0M	$-10.0M	$-15.0M	$-17.0M	$-20.0M	$-14.0M	$-16.0M	$-18.0M	$-25.0M
EPS	$-0.08	$-0.11	$-0.08	$-0.09	$-0.08	$-0.11	$-0.12	$-0.14	$-0.10	$-0.08	$-0.10	$-0.13

Over the 8 years reported for Compass Therapeutics, Inc., borrowings decreased from $15.0M in 2018 to $10.0M in 2025, cash stood at $31.0M in the latest year, shareholders' equity was $0, current assets covered current liabilities 15.00 times.

Balance Sheet — 8 Years (USD millions)

Metric	2018	2019	2020	2021	2022	2023	2024	2025
Total Assets	$65.0M	$30.0M	$52.0M	$154.0M	$200.0M	$157.0M	$140.0M	$220.0M
Current Assets	$59.0M	$26.0M	$50.0M	$147.0M	$195.0M	$154.0M	$133.0M	$210.0M
Cash	$58.0M	$25.0M	$47.0M	$145.0M	$35.0M	$24.0M	$43.0M	$31.0M
Inventory	$0	$0	$0	$0	$0	$0	$0	$0
Receivables	$0	$0	$0	$0	$0	$0	$0	$0
Fixed Assets	$5.0M	$4.0M	$1.0M	$6.0M	$5.0M	$3.0M	$7.0M	$9.0M
Capital Work in Progress	$0	$0	$0	$0	$0	$0	$0	$0
Investments	$0	$0	$0	$0	$152.0M	$128.0M	$83.0M	$178.0M
Other Assets	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$149.0M	$149.0M	$12.0M	$14.0M	$18.0M	$8.0M	$15.0M	$23.0M
Current Liabilities	$8.0M	$10.0M	$10.0M	$11.0M	$16.0M	$8.0M	$9.0M	$14.0M
Borrowings	$15.0M	$15.0M	$9.0M	$4.0M	$3.0M	$2.0M	$7.0M	$10.0M
Other Liabilities	$135.0M	$134.0M	$3.0M	$10.0M	$15.0M	$7.0M	$9.0M	$13.0M
Equity	$2.0M	$0	$0	$0	$0	$0	$0	$0
Reserves	$-85.0M	$-119.0M	$40.0M	$140.0M	$182.0M	$149.0M	$125.0M	$197.0M

For Compass Therapeutics, Inc., operating cash flow was positive in 0 of 8 reported years; free cash flow in the latest year was negative at $49.0M; free cash flow was positive in 0 of 8 years; financing activities used $1.0M in the latest year, which covers debt repayment, dividends and buybacks.

Cash Flow Statement — 8 Years (USD millions)

Metric	2018	2019	2020	2021	2022	2023	2024	2025
Operating Cash Flow	$-34.0M	$-32.0M	$-27.0M	$-20.0M	$-34.0M	$-41.0M	$-45.0M	$-49.0M
Investing Cash Flow	$-4.0M	$-1.0M	$0	$-3.0M	$-151.0M	$27.0M	$47.0M	$-93.0M
Financing Cash Flow	$64.0M	$0	$-6.0M	$0	$76.0M	$0	$-1.0M	$-1.0M
Net Cash Flow	$28.0M	$-32.0M	$22.0M	$97.0M	$-110.0M	$-11.0M	$19.0M	$-13.0M
Free Cash Flow	$-36.0M	$-32.0M	$-27.0M	$-21.0M	$-34.0M	$-41.0M	$-45.0M	$-49.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	-0.23
EV / EBITDA	-1.77
FCF Yield	-35.68%
Quick Ratio	11.22
Interest Coverage	—
Return 1Y	-36.34%
Return 3Y	-15.54%
Return 5Y	-55.31%

Compass Therapeutics, Inc. (CMPX) financials — frequently asked questions

What is Compass Therapeutics, Inc.'s annual revenue?

Compass Therapeutics, Inc. (CMPX) reported annual revenue of $0 in its most recent fiscal year.

What is Compass Therapeutics, Inc.'s net profit?

Compass Therapeutics, Inc. (CMPX) reported a net loss of $66.0M in its most recent fiscal year.

What is CMPX EV/EBITDA?

Compass Therapeutics, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is -1.77. A negative value means EBITDA was negative over the period, so the ratio is not a meaningful valuation measure.

Related stock screens

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks High ROE Stocks Low P/E Stocks High Net Margin Stocks Dividend Stocks Low Debt Stocks Nasdaq High ROE Stocks All stock screens

CMPX Overview CMPX Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.